



October 13, 2006

Peregrine Pharmaceuticals to Present at BIO InvestorForum

- Presentation to Be Webcast Live and Archived on Company's Website -

TUSTIN, Calif., Oct 13, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage products for the treatment of hepatitis C virus infection and cancer, today announced that senior management will present at the 2006 Biotechnology Industry Organization (BIO) InvestorForum on Thursday, October 19, 2006 at 11:40 am PDT, or 2:40 pm EDT. The presentation will be held in the Twin Peaks North Room at The Palace Hotel in San Francisco, CA.

Peregrine CEO and president Steven W. King will provide a review of recent corporate developments.

Mr. King's presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.peregrineinc.com. A replay will be available on the Peregrine website and archived for approximately 90 days.

For more information about this conference, please visit: <http://investorforum.bio.org/opencms/bif/2006/index.jsp>.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing five separate clinical trials in cancer and HCV infection with its lead product candidates bavituximab and Cotara® in the U.S. and India. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contacts:

GendeLLindheim BioCom Partners

Investors

info@peregrineinc.com

(800) 987-8256

Media

Barbara Lindheim

(212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.

Investors, +1-800-987-8256, info@peregrineinc.com, or Media, Barbara Lindheim, +1-212-918-4650, both of GendeLLindheim BioCom Partners, for Peregrine Pharmaceuticals, Inc.

<http://www.peregrineinc.com/>